IMIDIA Cohort 1

Study description

Primary purpose

Pancreatic tissue and blood samples from metabolically phenotyped pancreatectomised patients to identify transcriptomic changes in type 2 diabetic islets

Study types

identification of diagnostic biomarkers for treatment and monitoring in diabetes

Description of cohorts

IMIDIA cohort 1 participants

Study characteristics

Specimen collection protocol Total pancreatectomy, Partial pancreatectomy

Subjects

Organisms

Homo sapiens

Number of subjects

415

Diseases

impaired glucose tolerance type II diabetes impaired fasting glycaemia disease free type I diabetes type III diabetes

Sample sources

tissue sample

Samples collected

blood DNA RNA pancreas pancreatic islet

Demographic and participant information

Cohort characteristics

age at enrollment 23-86 year

height 1.48-2.04 meter

weight 38-142 kg

BMI 13.96-44.59 kg/m2

sex 233 male, 182 female

diabetes status 122 type II diabetes, 104 type III diabetes, 81 impaired glucose tolerance, 1 type I diabetes, 17 impaired fasting glycaemia, 59 non-diabetic

blood glucose in oral glucose tolerance test (0h) 0.07-12.26 mmol/L

blood glucose in oral glucose tolerance test (1h) 4.53-19.33 mmol/L

blood glucose in oral glucose tolerance test (2h) 2.44-21.50 mmol/L

Hemoglobin A1C 3.60-13.50 %

HOMA1-IR Index 0.00-61.00

HOMA1-B Index 0.20-960.00

HOMA1-S Index 0.03-277.43

Fasting Insulin IP 0.11-480.00 pmol/L

Fasting Insulin 0.02-69.12

Fasting Glucose IP 2.68-33.32 mmol/L

Fasting Insulin in serum 0.01-0.33 nmol/L

Insulin in serum (1h)) 0.03-2.13 nmol/L

Insulin in serum (2h) 0.03-2.91 nmol/L

Fasting C-peptide in serum 0.02-3.59

C-peptide in serum (1h) 0.62-8.02

C-peptide in serum (2h) 0.90-8.04

Fasting Proinsulin in serum 0.06-32.90 pmol/L

Proinsulin in serum (1h) 1.70-82.20 pmol/L

Proinsulin in serum (2h) 1.80-125.60 pmol/L

potassium in serum 0.94-5.75 mmol/L

magnesium in serum 0.44-4.82 mmol/L